[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:cdk12-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"CDK12 Gene",8,5,[8,16,22,29,35,41,48,55],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05011383","High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers",[12],"Phase 2","RECRUITING","2026-08-26T02:17:47.813245Z","2026-07-24T01:27:14.925238Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06844383","A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate",[12],"2026-08-26T02:17:43.321968Z","2026-05-05T02:43:29.708217Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT05687110","Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes",[26],"Phase 1","2026-08-26T02:17:58.890423Z","2026-05-05T02:43:27.808389Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT03786796","Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations",[12],"2026-08-26T02:18:38.077159Z","2026-05-05T02:35:31.766251Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT04706663","Precision-Based Genomics in Prostate Cancer",[],"2026-08-26T02:17:23.750999Z","2026-05-13T02:55:06.268346Z",{"nct_id":42,"title":43,"phases":44,"status":45,"updated_at":46,"content_modified":47},"NCT07723651","[18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)",[12],"NOT_YET_RECRUITING","2026-08-26T02:19:11.399072Z","2026-07-24T01:27:14.924205Z",{"nct_id":49,"title":50,"phases":51,"status":52,"updated_at":53,"content_modified":54},"NCT05498272","Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T02:05:27.322885Z","2026-05-05T02:43:27.674415Z",{"nct_id":56,"title":57,"phases":58,"status":52,"updated_at":59,"content_modified":60},"NCT04550494","Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations",[12],"2026-08-03T03:54:23.387833Z","2026-05-05T02:43:29.385344Z"]